Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
Research output: Contribution to journal › Journal article › Research › peer-review
Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
Original language | English |
---|---|
Journal | Lancet |
Volume | 362 |
Issue number | 9391 |
Pages (from-to) | 1184-91 |
Number of pages | 8 |
ISSN | 0140-6736 |
DOIs | |
Publication status | Published - 11 Oct 2003 |
ID: 34102049